Skip to main content

Table 4 Multivariate adjusted risk estimation of different systolic and diastolic blood pressure and pulse pressure quartiles for CV-mortality in the total population and those with and without anti-hypertensive medication: Tehran Lipid and Glucose study (1999–2014)

From: Blood pressure components and incident cardiovascular disease and mortality events among Iranian adults with chronic kidney disease during over a decade long follow-up: a prospective cohort study

  BP category Model 1 Model 2
  E/N HR (95% CI) p HR (95% CI) p
Total (N = 1232) SBP < 120 14/367 1.03 (0.47–2.23) 0.95 1.11 (0.51–2.42) 0.79
120 ≤ SBP < 130* 12/224 Ref    Ref   
130 ≤ SBP < 140 13/211 1.14 (0.52–2.49) 0.75 0.92 (0.41–2.05) 0.85
SBP ≥ 140 61/430 2.07 (1.11–3.86) 0.02 2.21 (1.16–4.22) 0.016
DBP < 80 43/544 3.69 (1.46–9.34) 0.006 3.0 (1.17–7.7) 0.022
80 ≤ DBP < 85* 5/242 Ref    Ref   
85 ≤ DBP < 90 17/165 5.13 (1.89–13.9) 0.001 5.48 (2.01–14.92) 0.001
DBP ≥ 90 35/281 6.36 (2.48–16.32) < 0.001 6.86 (2.66–17.7) < 0.001
PP < 40* 9/327 Ref    Ref   
40 ≤ PP < 50 19/291 1.69 (0.76–3.76) 0.19 1.58 (0.7–3.54) 0.27
50 ≤ PP < 64 23/307 1.44 (0.68–3.27) 0.31 1.25 (0.57–2.75) 0.58
PP ≥ 64 49/307 2.49 (1.20–5.20) 0.014 2.22 (1.06–4.64) 0.034
  1. Subjects with prevalent CVD were excluded for CV-mortality
  2. Model 1: Adjusted for sex
  3. Model 2: Adjusted for sex, BMI, diabetes, hypercholesterolemia, eGFR, smoking and anti-hypertensive medication (only for the total population). Age was adjusted by considering it as the time-scale
  4. CVD cardiovascular disease, BP blood pressure, SBP systolic blood pressure, DBP diastolic blood pressure, pp pulse pressure, E/N events/N, HR hazard ratio, CI confidence interval
  5. *Reference intervals